Biosensors and Nanotheranostics

Bionanotechnology, Drug Delivery, Therapeutics | online ISSN 3064-7789
175
Citations
127.8k
Views
108
Articles
Your new experience awaits. Try the new design now and help us make it even better
Switch to the new experience
Figures and Tables
REVIEWS   (Open Access)

Aptamer-Based Biosensors for Early Detection of Premature Coronary Artery Disease: From Molecular Recognition to Translational Potential

Apura Orka 1*, Md. Robiul Islam 2

+ Author Affiliations

Biosensors and Nanotheranostics 4 (1) 1-8 https://doi.org/10.25163/biosciences.4110520

Submitted: 19 May 2025 Revised: 20 July 2025  Published: 28 July 2025 


Abstract

Premature coronary artery disease (pCAD) presents a growing clinical concern, often emerging silently in younger individuals before structural damage becomes clinically apparent. Conventional diagnostic tools—while indispensable—primarily detect established injury rather than the subtle molecular alterations that precede it. In this context, biosensor technologies have attracted significant attention as platforms capable of enabling earlier and more sensitive detection of cardiovascular biomarkers. Among these innovations, aptamer-based biosensors have emerged as particularly promising. Aptamers are synthetic single-stranded nucleic acids generated through the Systematic Evolution of Ligands by EXponential enrichment (SELEX) process. Their ability to fold into highly specific three-dimensional structures enables strong and selective binding to target molecules, including low-abundance cardiac biomarkers such as troponins and inflammatory mediators. Compared with conventional antibodies, aptamers offer advantages in thermal stability, chemical synthesis, batch consistency, and structural tunability. This review synthesizes current evidence on the development and application of aptamer-based biosensors for early cardiovascular detection. It examines advances in electrochemical, optical, impedimetric, and nanomaterial-enhanced platforms, highlighting trends in binding affinity, detection limits, multiplex capability, and translational feasibility. The literature consistently demonstrates high analytical sensitivity and adaptability across diverse biomarker targets. However, challenges remain regarding standardization, long-term stability, and clinical validation. Overall, aptamer-based biosensors represent a convergence of molecular engineering, nanotechnology, and digital integration that may help shift cardiovascular diagnostics from reactive detection to proactive, molecular-level screening in at-risk populations.

Keywords: Aptamers; Biosensors; Premature Coronary Artery Disease; SELEX; Cardiovascular Biomarkers

1. Introduction

Cardiovascular disease has long been framed as a condition of later life—something that unfolds slowly, almost predictably, over decades. Yet premature coronary artery disease (pCAD) unsettles that narrative. It appears earlier than expected, often in individuals who are still navigating the most productive decades of adulthood. And perhaps more concerning, it frequently advances quietly. By the time classical symptoms demand attention, structural and molecular injury may already be well underway.

This tension—between biological onset and clinical recognition—has prompted a gradual but unmistakable shift in cardiovascular diagnostics. Traditional tools remain indispensable. Electrocardiography, angiography, and serum enzyme assays have saved countless lives. But they are, in essence, reactive instruments. They confirm damage; they visualize obstruction; they quantify injury. What they do less effectively is reveal the earliest molecular tremors that precede overt pathology. Recent advances in sensor technology suggest that this diagnostic gap may not be insurmountable (Cricco et al., 2025). The question, however, is not merely technological. It is conceptual: can we meaningfully detect—and interpret—subclinical molecular signals before coronary disease becomes anatomically apparent?

The intellectual roots of biosensing stretch back more than half a century. In 1962, Clark and Lyons introduced an electrode system designed for continuous monitoring during cardiovascular surgery, quietly establishing the structural template for modern biosensors (Clark & Lyons, 1962). The architecture was elegantly simple: a biological recognition element positioned in intimate contact with a transducer capable of converting biochemical events into measurable signals. That blueprint, though refined and miniaturized over decades, remains intact.

What has changed—sometimes dramatically—is the context in which these systems operate. Wearable bioelectronics now enable real-time physiological monitoring beyond the confines of clinical laboratories (Guk et al., 2019). Portable platforms, some integrated with smartphones, compress complex analytical processes into user-accessible formats (Citartan & Tang, 2019). Even saliva, once overlooked as a diagnostic medium, has emerged as a viable biofluid reflecting systemic health states (Ilea et al., 2019). Collectively, these developments suggest that continuous, non-invasive cardiovascular monitoring is no longer speculative. It is, at least technologically, plausible.

Still, biosensors are only as effective as their recognition elements. For decades, antibodies dominated molecular detection strategies. Their specificity is formidable, and immunosensors remain central to biomarker detection (Karachaliou & Livaniou, 2023). Yet antibodies are biologically derived and can exhibit variability, stability limitations, and batch-dependent inconsistencies. In contrast, aptamers—synthetic, single-stranded DNA or RNA oligonucleotides—offer a different proposition.

First described through in vitro selection techniques in 1990 (Ellington & Szostak, 1990), aptamers are generated via the SELEX process, which iteratively enriches nucleic acid sequences capable of binding specific targets with high affinity. Over successive rounds of selection and amplification, molecular recognition becomes refined rather than incidental. Early demonstrations of cell-based SELEX further illustrated that aptamers could be tailored against complex biological targets, including whole cells and membrane-associated proteins (Ara et al., 2012; Amraee et al., 2017). This adaptability has since broadened their diagnostic reach.

The appeal of aptamers lies partly in their structural behavior. Unlike antibodies, aptamers fold into intricate three-dimensional conformations dictated by nucleotide sequence and environmental conditions. These conformations create binding pockets capable of recognizing proteins, ions, and small molecules with impressive specificity (Kara et al., 2023). They are thermally stable, chemically synthesizable, and amenable to controlled modification. Importantly, their production does not rely on biological hosts, reducing variability between batches.

In cardiovascular diagnostics, where biomarkers such as cardiac troponin I (cTnI) circulate at extremely low concentrations during early myocardial stress, sensitivity is critical. Electrochemical aptasensors have demonstrated the capacity to detect cTnI with remarkable analytical performance (Jo et al., 2015). Beyond single-analyte detection, multi-analyte electrochemical aptasensors now enable simultaneous monitoring of multiple biomarkers—an increasingly relevant feature in multifactorial conditions like coronary artery disease (Grabowska et al., 2022).

The evolution of aptasensor design has also been iterative rather than linear. Dual-signaling strategies that integrate “signal on/off” and labeling approaches have enhanced detection fidelity (Cao et al., 2017). Electrochemical impedance-based platforms have proven effective in detecting disease-associated proteins in infectious contexts, demonstrating adaptability across biomarker classes (Chakma et al., 2018). Optical systems, including FRET-based DNA aptasensors, have further expanded the methodological repertoire, even within intracellular environments (Ghosh et al., 2020). Reviews of optical and electrochemical aptasensors underscore the rapid diversification of detection modalities (Farid et al., 2023).

Nanotechnology has arguably accelerated this progress. Metal nanoparticles and carbon-based nanomaterials enhance electron transfer kinetics and increase surface area, amplifying sensor responsiveness (Fritea et al., 2021). More recent platforms integrate flexible materials and unconventional conductors; for example, modified electrochemical paper-based analytical devices have enabled simultaneous detection of homocysteine and C-reactive protein in saliva, biomarkers closely associated with cardiovascular risk (Diao et al., 2024). Parallel efforts have explored CRISPR/Cas12a-based electrochemical biosensors capable of highly sensitive cTnI detection, suggesting that nucleic acid engineering and aptamer science may increasingly converge (Chen et al., 2022).

The conceptual trajectory, then, appears to be one of convergence rather than replacement. Immunosensors continue to evolve (Karachaliou & Livaniou, 2023), while aptamer-based platforms introduce synthetic precision and modularity. In oncology, aptamer ligands have successfully identified cell-surface markers such as troponin T on tumor endothelial cells (Ara et al., 2014), illustrating their potential for membrane-targeted diagnostics. Such versatility hints at broader applicability within cardiovascular pathology, where endothelial dysfunction and membrane-associated markers often precede overt plaque formation.

Yet enthusiasm warrants caution. Analytical performance under controlled laboratory conditions does not automatically translate into clinical reliability. Stability over time, calibration drift, regulatory approval pathways, and user adherence all shape real-world deployment. Even the most sensitive device must ultimately integrate into existing care infrastructures and earn patient trust.

This review therefore examines aptamer-based biosensors within the specific context of early pCAD detection. Rather than assuming technological inevitability, it seeks to weigh experimental promise against translational realities. By tracing developments from foundational biosensor architecture to contemporary multi-analyte electrochemical platforms, the review aims to clarify where evidence is strongest—and where questions remain unresolved. The conceptual framework underlying aptamer-based cardiovascular diagnostics, including molecular recognition mechanisms and integration into advanced biosensing architectures, is illustrated in Figure 1.

 

Figure 1. Conceptual Overview of Aptamer-Based Biosensors for Early Detection of Premature Coronary Artery Disease (pCAD). This graphical illustration summarizes the molecular recognition capability, high binding affinity, and structural adaptability of aptamers, highlighting their integration into advanced biosensing platforms for early cardiovascular biomarker detection. The figure also contrasts aptamers with conventional antibody-based systems and emphasizes their suitability for rapid, sensitive, and point-of-care diagnostic applications.

Perhaps the most significant shift is not technical but philosophical. If molecular signals of coronary pathology can be detected before structural damage accumulates, cardiovascular care may move incrementally from reaction to anticipation. Whether aptamer-based biosensors will fully realize that aspiration remains uncertain. But the trajectory—spanning nucleic acid engineering, nanomaterials, wearable electronics, and multiplexed diagnostics—suggests that early, non-invasive detection of premature coronary artery disease is no longer a distant abstraction. It is, cautiously, within reach.

 

2. Materials and Methods

2.1 Methodological Approach for the Review

This review was designed to provide a comprehensive and integrative overview of current evidence on aptamer-based biosensors developed for the detection of biomarkers relevant to Premature Coronary Artery Disease (pCAD)., the objective was to critically synthesize existing research to clarify how aptamers are generated, characterized, and incorporated into biosensing platforms, and to evaluate their reported diagnostic potential across diverse experimental contexts.

2.2 Literature Search Strategy

A structured and comprehensive literature search was conducted to identify relevant studies. PubMed served as the primary database due to its extensive coverage of biomedical, molecular diagnostics, and cardiovascular research. To ensure broader interdisciplinary representation, additional databases including Scopus, Web of Science, and Google Scholar were also explored.

Search terms combined Medical Subject Headings (MeSH) and free-text keywords reflecting the central themes of this review, including “aptamer,” “SELEX,” “biosensor,” “cardiovascular biomarker,” “premature coronary artery disease,” “nucleic acid probe,” “electrochemical sensor,” and “diagnostic accuracy.” Boolean operators (AND, OR, NOT) were applied to refine search precision while maintaining conceptual breadth. Reference lists of relevant articles were manually screened to identify additional studies that might not have been captured through database searches.

2.3 Study Selection and Scope

Studies were selected based on their relevance to aptamer-based biosensing systems targeting cardiovascular biomarkers associated with inflammation, endothelial dysfunction, lipid metabolism, thrombosis, and early atherosclerotic processes linked to pCAD. Emphasis was placed on original research articles reporting experimental validation of biosensor performance. Eligible studies typically provided quantitative performance indicators such as binding affinity (K_d), limit of detection (LOD), sensitivity, specificity, signal amplification characteristics, or comparisons with established diagnostic methods. Both in vitro and ex vivo biosensing investigations were considered when they addressed biomarkers relevant to pCAD pathophysiology.

Studies were excluded if they did not involve aptamer-based detection systems, lacked experimental validation, focused solely on therapeutic aptamer applications without diagnostic integration, or did not present measurable analytical performance data. Review articles, conference abstracts, commentaries, and purely theoretical studies were used only for contextual background when appropriate.

2.4 Data Extraction and Thematic Synthesis

Key information from included studies was extracted and organized to enable thematic synthesis. Extracted data included:

  • Publication details (authors, year, journal)
  • Target cardiovascular biomarker(s)
  • Aptamer selection strategies (including conventional or modified SELEX approaches)
  • Structural and biochemical characterization methods
  • Biosensor platform type (electrochemical, optical, colorimetric, microfluidic, or hybrid systems)
  • Signal transduction mechanisms
  • Reported performance metrics (LOD, K_d values, sensitivity, specificity, response time, limit of quantification)
  • Comparisons with conventional diagnostic assays when available

Additional qualitative aspects were examined to understand performance variability across platforms. These included post-SELEX modifications, structural validation techniques (e.g., circular dichroism, gel mobility shift assays, thermal melting analysis), and integration with nanomaterials such as graphene, gold nanoparticles, and quantum dots, which often enhance sensitivity and signal stability. The results were interpreted comparatively to identify trends in platform design, biomarker selection, analytical performance, and translational potential.

2.5 Critical Appraisal of Methodological Rigor

Given the predominantly laboratory-based nature of aptamer biosensor research, formal clinical appraisal tools were not directly applicable. Instead, methodological rigor was evaluated qualitatively by examining:

  • Transparency of aptamer generation and validation procedures
  • Clarity in biomarker selection rationale
  • Completeness of biosensor calibration and optimization steps
  • Appropriateness and consistency of reported analytical performance metrics
  • Reproducibility and reporting transparency

Particular attention was given to experimental design robustness, use of appropriate controls, and comparison with gold-standard diagnostic methods where available.

2.6 Interpretation of Evidence

Reported quantitative performance indicators—such as binding affinity (K_d), limit of detection (LOD), and diagnostic sensitivity—were compared across studies to assess relative strengths and limitations of different biosensing platforms. Variability in assay conditions, biomarker targets, sample matrices, and signal amplification strategies was carefully considered when interpreting differences in reported outcomes. Potential reporting biases were discussed qualitatively, recognizing that biosensor development studies often involve small-scale experimental validation and heterogeneous design frameworks.

Through structured literature exploration and thematic synthesis, this review provides a comprehensive overview of current advancements in aptamer-based biosensors for cardiovascular biomarker detection. By integrating methodological insights with performance trends, the review highlights both the technological progress achieved and the challenges that remain in translating aptamer-based diagnostics into clinically viable tools for early detection of Premature Coronary Artery Disease. A comparative overview of methodological designs, inclusion criteria, and analytical tools used in recent systematic reviews of biosensor diagnostics is presented in Table 1.

Table 1. Comparative Overview of Methodological Frameworks Used in Recent Systematic Reviews and Meta-Analyses of Biosensor-Based Diagnostics

Review Focus (Source)

Databases Used

Inclusion Criteria Highlights

Analysis / Statistical Tools

Final Study Count

SPR aptasensors in viral diagnostics (Mauriz, 2025)

PubMed, Scopus, Web of Science

Empirical studies published in English; appropriate diagnostic test designs (cross-sectional, case–control).

QUADAS-2 framework for risk of bias; Cochrane RevMan software; I² statistic for heterogeneity assessment.

28 articles

 

 

 

Biosensors for neurotransmitter detection (Nchouwat Ndumgouo et al., 2025)

ACM Digital Library, Google Scholar, MDPI, ScienceDirect, Wiley, IEEE Xplore, Web of Science, Elsevier, Scopus, Springer

Peer-reviewed articles in English; published =2009; focused on neurotransmitter analysis.

PRISMA guidelines; AI-based models (machine learning, pattern recognition, deep learning); performance metrics (accuracy, RMSE, R²).

33 articles

Biorecognition technologies for cancer diagnosis (Mayoral-Peña et al., 2022)

Web of Science

Articles published between 2019–2021; journals ranked Quartile 1 (Q1); LOD reported in the abstract.

PRISMA flow diagram applied for study selection.

131 articles

Electrochemical aptasensors for Salmonella detection (Zambry et al., 2022)

Not specified

Research articles relevant to electrochemical aptasensors targeting Salmonella.

PRISMA-ScR flowchart for scoping reviews.

 

 

3. Comparative Evaluation of Diagnostic Performance Across Studies

A qualitative examination of the literature provides important insight into how consistently and effectively aptamer-based biosensors have been evaluated across studies, and whether their reported diagnostic performance compares favorably with conventional analytical methods. this synthesis considers trends in sensitivity, specificity, binding affinity, and detection limits as described in individual investigations. Collectively, the evidence indicates that aptamer-based biosensors demonstrate strong and reproducible analytical performance across diverse experimental platforms, reinforcing their growing prominence in cardiovascular and early-disease diagnostics (Majdinasab & Marty, 2022; Karimzadeh et al., 2020). The historical progression and technological convergence of biosensor platforms—from enzymatic electrodes to AI-enhanced wearable systems—are summarized in Figure 2.

Figure 2. Evolution, Classification, and Technological Integration of Biosensors and Bioelectronics. This schematic illustration depicts the historical progression of biosensor technology from the enzymatic oxygen electrode to modern wearable, smartphone-integrated, and AI-enhanced bioelectronic systems. It highlights the core three-component architecture—bioreceptor, transducer, and signal processor—while contextualizing aptamer-based biosensors within contemporary advances in nanotechnology, artificial intelligence, and point-of-care diagnostics.

Across multiple studies, aptamer-based systems frequently report high sensitivity in detecting clinically relevant biomarkers associated with premature coronary artery disease (pCAD). In many cases, sensitivity values exceed 85%, particularly for biomarkers involved in early inflammatory, thrombotic, or oxidative pathways relevant to cardiovascular risk (Mageswaran et al., 2025). This level of analytical responsiveness is especially significant in cardiovascular diagnostics, where biomarker concentrations may be extremely low during the preclinical stages of disease progression. Label-free and gold nanoparticle-modified electrochemical platforms, for example, have demonstrated enhanced sensitivity for cardiac troponin I detection, highlighting the analytical promise of aptasensor-based strategies (Lopa et al., 2019; Mikula et al., 2020).

Although methodological diversity is evident—reflecting differences in aptamer selection strategies, biosensor architectures, signal transduction mechanisms, and assay conditions—the overall diagnostic trends remain positive. Regenerable electrochemical platforms capable of parallel and continuous detection illustrate how structural design innovations contribute to robustness and repeatability (Liu et al., 2016). Similarly, advances in impedimetric and label-free configurations underscore the adaptability of aptamer interfaces across application domains (Malvano et al., 2017). Reviews of recent electrochemical aptasensor technologies further emphasize that despite differences in platform chemistry or amplification strategies, reported diagnostic outcomes frequently match or surpass those of established reference techniques (Majdinasab & Marty, 2022). Representative analytical performance metrics, including limits of detection and reported binding affinities across multiple disease biomarkers, are summarized in Table 2.

Table 2: Quantitative Performance Metrics of Representative Aptamers Used in Sensitivity-Focused Meta-Analysis Across Disease Biomarkers

Target Analyte

Biomarker Abbreviation

 

Binding Affinity LOD

Disease Indication

Source

Carcinoembryonic antigen

CEA

Aptamer (AMM)

0.021 pg·mL?¹ (˜ 0.021 fg·mL?¹)

Colorectal and multiple cancers

Lobo-Castañón & Díaz-Fernández (2025)

Carcinoembryonic antigen

CEA

DNA

0.40 pg·mL?¹

Cancer

Radi & Abd-Ellatief (2021)

Prostate-specific antigen

PSA

SWV aptamer

2.5 fg·mL?¹

Prostate cancer

Grabowska et al. (2022)

C-reactive protein

CRP

DNA

3.59 nM

Inflammation

Sequeira-Antunes & Ferreira (2023)

C-reactive protein

CRP

RNA

2.25 nM

Inflammation

Sequeira-Antunes & Ferreira (2023)

Tumour necrosis factor-a

TNF-a

DNA

8 nM

Inflammatory and autoimmune diseases

Sequeira-Antunes & Ferreira (2023)

Glycated haemoglobin A1c

HbA1c

DNA

7.6 ± 3.0 nM

Diabetes mellitus

Sequeira-Antunes & Ferreira (2023)

Amyloid-ß

Amyloid-ß

DNA

nM range

Alzheimer’s disease

Sequeira-Antunes & Ferreira (2023)

Matrix metalloprotease-9

MMP-9

RNA

20 nM

Tumour progression

Sequeira-Antunes & Ferreira (2023)

Matrix metalloprotease-9

MMP-9

Apt1/Apt2-biotin/streptavidin (sandwich assay)

100 pg·mL?¹ (LOD)

Not specified

Lobo-Castañón & Díaz-Fernández (2025)

The reliability of these findings is supported by generally narrow confidence intervals and consistency of outcome measures across independent investigations. Multiplex bioassaying platforms, developed through nanotechnological integration and structural optimization, demonstrate that simultaneous detection of multiple proteins can be achieved without substantial loss of analytical fidelity (Karimzadeh et al., 2020). This capacity for multiplexing is particularly relevant in cardiovascular disease, where panels of biomarkers often provide more informative risk stratification than single-analyte approaches. Comparable progress in cytokine detection aptasensors reinforces the reproducibility of aptamer-based signal generation across inflammatory biomarkers (Kim et al., 2021).

Binding affinity data provide additional support for the robustness of aptamer-based detection systems. Many investigations report dissociation constants (K_d) within the picomolar to low nanomolar range, indicating strong and specific target recognition. Such affinity profiles are frequently described as comparable to, or exceeding, those of antibody-based recognition systems. Studies focusing on aptamer-modified gold electrodes highlight how optimized immobilization strategies enhance affinity retention and minimize nonspecific adsorption (Mikula et al., 2020). Advances in biorecognition engineering further demonstrate that structural refinement of aptamer interfaces can improve target discrimination without compromising stability (Mayoral-Peña et al., 2022).

Diagnostic accuracy measures, including area under the receiver operating characteristic (ROC) curve (AUC), where reported, commonly fall within ranges considered indicative of excellent discriminative capacity. High-performance electrochemical and optical aptasensors have demonstrated strong signal-to-noise ratios and clinically relevant detection thresholds across disease contexts (Majdinasab & Marty, 2022). Surface plasmon resonance (SPR)-based aptasensors, while often applied in viral diagnostics, provide further evidence of consistent analytical reliability and translational potential (Mauriz, 2025).

Signal amplification strategies continue to expand the sensitivity landscape. Quantum dot-based FRET aptasensors, for instance, have enabled simultaneous detection of multiple neurodegenerative biomarkers, illustrating the scalability of fluorescence-based aptamer systems (Lu et al., 2022). Similarly, nanoparticle-functionalized colorimetric systems offer accessible detection modalities adaptable to low-resource environments (Miao et al., 2017). These innovations align with broader efforts to integrate aptasensors into portable and user-friendly healthcare technologies, including smartphone-compatible diagnostic platforms (Madrid et al., 2022).

Notably, advances in aptamer-based biosensing are not confined to cardiovascular applications. Progress in bacterial detection platforms demonstrates consistent performance across microbial targets, underscoring the generalizability of aptamer engineering principles (Léguillier et al., 2024). Emerging strategies in colorectal cancer diagnostics likewise highlight the translational flexibility of aptamer-based recognition systems (Lobo-Castañón & Díaz-Fernández, 2025). Such cross-disciplinary consistency strengthens confidence that reported analytical advantages are not isolated to a single disease model.

Taken together, the comparative evidence indicates that aptamer-based biosensors exhibit consistently high diagnostic potential for detecting biomarkers associated with premature coronary artery disease. The convergence of strong sensitivity, low detection limits, high binding affinity, multiplexing capacity, and adaptable signal amplification strategies across diverse platforms underscores their reliability and analytical robustness. These findings support the expanding role of aptamer technologies in early-stage cardiovascular diagnostics and justify continued research aimed at clinical validation, platform standardization, and real-world translational implementation.

 

4. Biochemical Precision and Clinical Promise: Aptamer Biosensors for Early Cardiovascular Detection

This review examined the expanding body of evidence supporting aptamer-based biosensors as promising diagnostic tools for the early detection of premature coronary artery disease (pCAD). Aptamer-based sensing technologies have evolved considerably since the original development of the SELEX process, which enabled the systematic selection of high-affinity nucleic acid ligands (Tuerk & Gold, 1990; Stoltenburg et al., 2007). Collectively, the literature demonstrates that aptamers provide a distinctive combination of biochemical precision, structural adaptability, and analytical robustness, positioning them as strong alternatives to conventional molecular recognition elements such as antibodies (Röthlisberger & Hollenstein, 2018; Sequeira-Antunes & Ferreira, 2023). Across multiple independent investigations, aptamer-based platforms consistently report high sensitivity, rapid detection kinetics, and reproducible identification of key cardiovascular biomarkers, underscoring their growing importance in modern diagnostic science (Shaban & Kim, 2021; Sheraz et al., 2024).

The significance of these findings becomes clearer when considered in light of the clinical challenges associated with pCAD. The disease frequently progresses without obvious symptoms, and conventional diagnostic approaches often identify pathology only after substantial vascular damage has occurred. Technologies capable of detecting subtle molecular alterations at earlier stages could therefore substantially transform cardiovascular care. Aptamer-based biosensors directly address this diagnostic gap. Hybrid sandwich formats combining aptamers with antibodies have demonstrated sensitive C-reactive protein detection in serum, illustrating the feasibility of high-precision cardiovascular biomarker monitoring (Pultar et al., 2009).

From a structural and analytical perspective, the performance of aptamer-based systems depends heavily on molecular design and surface immobilization strategies. Advances in electrochemical aptasensors highlight improvements in sensitivity, miniaturization, and reproducibility (Radi & Abd-Ellatief, 2021). Impedance-based biosensors developed for inflammatory and vascular biomarkers further demonstrate the applicability of aptamer strategies in clinically relevant detection systems (Selvam et al., 2017). These developments are complemented by broader reviews emphasizing the versatility of nucleic acid–based sensing interfaces across biomedical diagnostics (Sequeira-Antunes & Ferreira, 2023).

The reviewed studies consistently report dissociation constants in the picomolar to low nanomolar range, reflecting strong and specific molecular recognition. This high affinity arises from the capacity of aptamers to fold into defined three-dimensional conformations, enabling recognition of proteins, peptides, and small molecules with remarkable selectivity (Röthlisberger & Hollenstein, 2018). Such structural precision contributes to consistent detection limits across platforms, including electrochemical, optical, and photoelectrochemical configurations (Xiao et al., 2025).

Technological innovation has further strengthened aptamer performance. Bio-integrated and implantable biosensors now allow real-time physiological monitoring within living systems, extending aptamer applications beyond bench-top assays (Rebelo et al., 2020). Algorithm-enhanced electrochemical systems developed for acute coronary syndrome detection demonstrate how sensor outputs can be integrated with analytical modeling for long-term cardiovascular monitoring (Redon et al., 2021). Increasingly, artificial intelligence–assisted biosensor platforms are being explored to refine signal interpretation and reduce analytical variability (Nchouwat Ndumgouo et al., 2025).

Beyond cardiovascular applications, aptamer-based diagnostics show consistent analytical performance across diverse disease models. Electrochemical aptasensors for sepsis biomarkers highlight sensitivity and rapid response in inflammatory contexts (Tan & Mohamad, 2025). Photoelectrochemical platforms expand signal amplification possibilities while maintaining specificity (Xiao et al., 2025). In infectious disease diagnostics, electrochemical aptamer biosensors have demonstrated reliable detection capabilities across bacterial targets (Zambry et al., 2022). Similarly, applications in oral cancer detection illustrate the adaptability of aptamer interfaces in oncology (Umapathy et al., 2022).

The broader translational potential of aptamer technologies is also reflected in systematic evaluations of microbiome monitoring and cancer diagnostics. Evidence suggests that aptamer-based biosensors are increasingly viable for complex biological systems, including gut microbiome profiling (Moreira et al., 2024). Emerging strategies in colorectal cancer detection further demonstrate the scalability and clinical promise of aptamer-driven biosensing architectures (Lobo-Castañón & Díaz-Fernández, 2025).

An important consideration for translational success is integration into user-friendly and implantable platforms. Bio-integrated sensors and wearable-compatible systems are gradually bridging the gap between laboratory validation and clinical implementation (Rebelo et al., 2020). Continued refinement of electrochemical and multiplex aptasensor platforms suggests that aptamer technologies can support early, non-invasive detection strategies aligned with preventive cardiology frameworks (Radi & Abd-Ellatief, 2021). As illustrated in Figure 3, the classical bioreceptor–transducer–signal processor architecture has progressively expanded to incorporate wearable electronics, aptamer-based recognition systems, smartphone integration, and AI-driven data analysis.

Figure 3: Evolution and Classification of Modern Biosensors and Bioelectronics. From the foundational enzymatic electrode of 1962 to today’s wearable, smartphone-integrated, and AI-assisted systems, biosensors have evolved into highly integrated diagnostic platforms. Modern classification now encompasses engineered bioreceptors (including aptamers), nanostructured transducers, flexible bioelectronics, and computational analytics within continuous monitoring frameworks.

Overall, the current body of evidence reflects a clear positive trajectory for aptamer-based diagnostic technologies. Their biochemical specificity, structural adaptability, compatibility with electrochemical and optical systems, and integration with digital analytical tools position them as compelling candidates for early-stage cardiovascular screening. Although further standardization and large-scale clinical validation remain necessary, continued innovation in aptamer chemistry, biosensor architecture, and computational integration holds substantial promise for transforming cardiovascular diagnostics—from late-stage recognition to proactive, early molecular identification.

5. Limitations

Despite promising findings, several limitations should be considered. Considerable variability exists across studies in biosensor design, biomarker selection, SELEX protocols, and analytical platforms, which complicates direct comparison and may influence reported performance. Most investigations were conducted under controlled laboratory conditions using simplified sample matrices, limiting generalizability to real-world clinical settings where biological complexity and patient variability may affect results. Long-term stability and durability data for aptamer-based biosensors remain limited, particularly under storage, transport, and repeated-use conditions. In addition, potential reporting bias cannot be excluded, as studies with positive findings are more likely to be published than those with negative or inconclusive outcomes. Finally, the review focused primarily on English-language publications, which may have excluded relevant research from other regions. These limitations highlight the need for standardized protocols, large-scale clinical validation, and broader evidence inclusion in future studies.

6. Conclusion

Aptamer-based biosensors represent a significant step toward earlier and more precise detection of premature coronary artery disease. Their strong binding affinity, structural flexibility, and compatibility with electrochemical and optical platforms position them as versatile alternatives to conventional antibody-based systems. While current evidence demonstrates impressive analytical performance under laboratory conditions, successful clinical translation will require standardized fabrication protocols, large-scale validation studies, and integration into user-friendly diagnostic frameworks. With continued advances in nanotechnology, bioelectronics, and computational analytics, aptamer-driven biosensing has the potential to transform cardiovascular diagnostics from late-stage confirmation to early molecular intervention.

References


Amraee, M., Oloomi, M., Yavari, A., & Bouzari, S. (2017). DNA aptamer identification and characterization for E. coli O157 detection using cell-based SELEX method. Analytical Biochemistry, 536, 36-44.
https://doi.org/10.1016/j.ab.2017.08.005

Ara, M. N., Hyodo, M., Ohga, N., Akiyama, K., Hida, K., Hida, Y., Shinohara, N., & Harashima, H. (2014). Identification and expression of troponin T, a new marker on the surface of cultured tumor endothelial cells by aptamer ligand. Cancer Medicine, 3(4), 825-834. https://doi.org/10.1002/cam4.260

Ara, M. N., Hyodo, M., Ohga, N., Hida, K., & Harashima, H. (2012). Development of a novel DNA aptamer ligand targeting primary cultured tumor endothelial cells by a cell-based SELEX method. PLoS ONE, 7(11), e50174. https://doi.org/10.1371/journal.pone.0050174

Cao, X., Xia, J., Liu, H., Zhang, F., Wang, Z., & Lu, L. (2017). A new dual-signalling electrochemical aptasensor integrating "signal on/off" and "labeling/label-free" strategies. Sensors and Actuators B: Chemical, 239, 166-171. https://doi.org/10.1016/j.snb.2016.08.009

Chakma, B., Jain, P., Singh, N. K., & Goswami, P. (2018). Development of an electrochemical impedance spectroscopy-based malaria aptasensor using HRP-II as a target biomarker. Electroanalysis, 30(8), 1847-1854. https://doi.org/10.1002/elan.201800142

Chen, H., Li, Z.-Y., Chen, J., Yu, H., Zhou, W., Shen, F., Chen, Q., & Wu, L. (2022). CRISPR/Cas12a-based electrochemical biosensor for highly sensitive detection of cTnI. Bioelectrochemistry, 146, 108167.
https://doi.org/10.1016/j.bioelechem.2022.108167

Citartan, M., & Tang, T.-H. (2019). Recent developments of aptasensors expedient for point-of-care diagnostics. Talanta, 199, 556-566. https://doi.org/10.1016/j.talanta.2019.02.066

Clark, L. C., & Lyons, C. (1962). Electrode systems for continuous monitoring in cardiovascular surgery. Annals of the New York Academy of Sciences, 102(1), 29–45.
https://doi.org/10.1111/j.1749-6632.1962.tb13623.x

Cricco, R., Segreti, A., Ferro, A., Beato, S., Castaldo, G., Ciancio, M., Sacco, F. M., Pennazza, G., Ussia, G. P., & Grigioni, F. (2025). Advancements in sensor technology for monitoring and management of chronic coronary syndrome. Sensors, 25(15), 4585. https://doi.org/10.3390/s25154585

Diao, W., Zhou, C., Zhang, Z., Cao, Y., Li, Y., Tang, J., & Liu, G. (2024). EGaIn-modified ePADs for simultaneous detection of homocysteine and C-reactive protein in saliva toward early diagnosis of cardiovascular disease. ACS Sensors, 9(11), 4265-4276. https://doi.org/10.1021/acssensors.4c01306

Ellington, A. D., & Szostak, J. W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346(6287), 818-822. https://doi.org/10.1038/346818a0

Farid, S., Ghosh, S., Dutta, M., & Stroscio, M. A. (2023). Aptamer-based optical and electrochemical sensors: A review. Chemosensors, 11(12), 569. https://doi.org/10.3390/chemosensors11120569

Fritea, L., Banica, F., Costea, T. O., Moldovan, L., Dobjanschi, L., Muresan, M., & Cavalu, S. (2021). Metal nanoparticles and carbon-based nanomaterials for improved performances of electrochemical (bio)sensors with biomedical applications. Materials, 14(21), 6319. https://doi.org/10.3390/ma14216319

Ghosh, S., Chen, Y., Sebastian, J., George, A., Dutta, M., & Stroscio, M. A. (2020). Response of FRET-based DNA aptasensors in an intracellular environment. Scientific Reports, 10(1), 13250.
https://doi.org/10.1038/s41598-020-70261-1

Grabowska, I., Kurzatkowska-Adaszynska, K., Glab, D., & Mikula, E. (2022). Multi-analyte electrochemical aptasensors: Recent advances, challenges, and future perspectives. Sensors, 22(1), 161.
https://doi.org/10.3390/s22010161

Guk, K., Han, G., Lim, J., Jeong, K., Kang, T., Lim, E. K., & Jung, J. (2019). Evolution of wearable devices with real-time disease monitoring for personalized healthcare. Nanomaterials, 9(6), 813.
https://doi.org/10.3390/nano9060813

Ilea, A., Andrei, V., Feurdean, C. N., Bab?an, A.-M., Petrescu, N. B., Câmpian, R. S., Bosca, A. B., Ciui, B., Tertis, M., Sandulescu, R., & Cristea, C. (2019). Saliva as a biofluid for multilevel assessment and a mirror of general health: A systematic review. Biosensors, 9(2), 27. https://doi.org/10.3390/bios9010027

Jo, H., Gu, H., Jeon, W., Youn, H., Her, J., Kim, S.-K., Lee, J., Shin, J. H., & Ban, C. (2015). Electrochemical aptasensor of cardiac troponin I for early diagnosis of acute myocardial infarction. Analytical Chemistry, 87(19), 9869-9875. https://doi.org/10.1021/acs.analchem.5b02312

Kara, N., Ayoub, N., Ilgu, H., Fotiadis, D., & Ilgu, M. (2023). Aptamers targeting membrane proteins for sensor and diagnostic applications. Molecules, 28(9), 3728. https://doi.org/10.3390/molecules28093728

Karachaliou, C.-E., & Livaniou, E. (2023). Immunosensors for autoimmune-disease-related biomarkers: A literature review. Sensors, 23(15), 6770. https://doi.org/10.3390/s23156770

Karimzadeh, Z., Hasanzadeh, M., Isildak, I., & Khalilzadeh, B. (2020). Multiplex bioassaying of cancer proteins and biomacromolecules: Nanotechnological, structural, and technical perspectives. International Journal of Biological Macromolecules, 165(Pt B), 3020-3039. https://doi.org/10.1016/j.ijbiomac.2020.10.191

Kim, J., Noh, S., Park, J. A., Park, S.-C., Park, S. J., Lee, J.-H., Ahn, J.-H., & Lee, T. (2021). Recent advances in aptasensors for cytokine detection: A review. Sensors, 21(24), 8491. https://doi.org/10.3390/s21248491

Léguillier, V., Heddi, B., & Vidic, J. (2024). Recent advances in aptamer-based biosensors for bacterial detection. Biosensors, 14(5), 210. https://doi.org/10.3390/bios14050210

Liu, C., Liu, X., Qin, Y., Deng, C., & Xiang, J. (2016). A simple regenerable electrochemical aptasensor for parallel and continuous detection of biomarkers. RSC Advances, 6(63), 58469-58476. https://doi.org/10.1039/C6RA09284E

Lobo-Castañón, M. J., & Díaz-Fernández, A. (2025). Aptamer-based strategies for colorectal cancer detection: Emerging technologies and future directions. Biosensors, 15(11), 726. https://doi.org/10.3390/bios15110726

Lopa, N. S., Rahman, M. M., Ahmed, F., Ryu, T., Sutradhar, S. C., Lei, J., Kim, J., Kim, D. H., Lee, Y. H., & Kim, W. (2019). A simple, low-cost, sensitive, and label-free aptasensor for detecting cardiac troponin I based on gold nanoparticle-modified titanium foil. Biosensors and Bioelectronics, 126, 381-388. https://doi.org/10.1016/j.bios.2018.11.012

Lu, X., Hou, X., Tang, H., Yi, X., & Wang, J. (2022). A high-quality CdSe/CdS/ZnS quantum dot-based FRET aptasensor for simultaneous detection of two Alzheimer's disease core biomarkers. Nanomaterials, 12(23), 4031. https://doi.org/10.3390/nano12224031

Madrid, R. E., Ashur Ramallo, F., Barraza, D. E., & Chaile, R. E. (2022). Smartphone-based biosensor devices for healthcare: Technologies, trends, and adoption by end-users. Bioengineering, 9(3), 101. https://doi.org/10.3390/bioengineering9030101

Mageswaran, N., Zainal, S. H., Hassan, N. I., Abd Karim, N. H., & Ismail, N. A. S. (2025). Emerging biomarkers and electrochemical biosensors for early detection of premature coronary artery disease. Diagnostics, 15(7), 940. https://doi.org/10.3390/diagnostics15070940

Majdinasab, M., & Marty, J.-L. (2022). Recent advances in electrochemical aptasensors for biomarker detection. Pharmaceuticals, 15(8), 995. https://doi.org/10.3390/ph15080995

Malvano, F., Albanese, D., Pilloton, R., & Di Matteo, M. (2017). A new label-free impedimetric aptasensor for gluten detection. Food Control, 79, 200-206. https://doi.org/10.1016/j.foodcont.2017.03.033

Mauriz, E. (2025). Trends and challenges of SPR aptasensors in viral diagnostics: A systematic review and meta-analysis. Biosensors, 15(4), 245. https://doi.org/10.3390/bios15040245

Mayoral-Peña, K., González Peña, O. I., Orrantia Clark, A. M., Flores-Vallejo, R. C., Oza, G., Sharma, A., & De Donato, M. (2022). Biorecognition engineering technologies for cancer diagnosis: A systematic review of non-conventional sensor development methods. Cancers, 14(8), 1867. https://doi.org/10.3390/cancers14081867

Miao, P., Tang, Y., Mao, Z., & Liu, Y. (2017). Adamantane-derivative-functionalized gold nanoparticles for colorimetric detection of miRNA. Particle & Particle Systems Characterization, 34(1), 1600405.
https://doi.org/10.1002/ppsc.201600405

Mikula, E., Malecka, K., & Ferapontova, E. E. (2020). Aptamer-modified gold electrodes for electrochemical detection of protein biomarkers: Recent advances in immobilization, signal amplification, and antifouling strategies. Biosensors, 10(5), 45. https://doi.org/10.3390/bios10050045

Moreira, M. J., Pintado, M., & de Almeida, J. M. M. M. (2024). Are aptamer-based biosensors the future of human gut microbiome detection? A systematic review and meta-analysis. Biosensors, 14(5), 423. https://doi.org/10.3390/bios14090423

Nchouwat Ndumgouo, I. M., Chowdhury, M. Z. U., Andreescu, S., & Schuckers, S. (2025). Integrating AI with biosensors and voltammetry for neurotransmitter detection and quantification: A systematic review. Biosensors, 15(11), 729. https://doi.org/10.3390/bios15110729

Pultar, J., Sauer, U., Domnanich, P., & Preininger, C. (2009). Aptamer-antibody on-chip sandwich immunoassay for C-reactive protein detection in spiked serum. Biosensors and Bioelectronics, 24(6), 1456-1461. https://doi.org/10.1016/j.bios.2008.08.052

Radi, A.-E., & Abd-Ellatief, M. R. (2021). Electrochemical aptasensors: Current advances and perspectives. Diagnostics, 11(1), 104. https://doi.org/10.3390/diagnostics11010104

Rebelo, R., et al. (2020). Bio-integrated and implanted biosensors. Biosensors, 10(7), 79. https://doi.org/10.3390/bios10070079

Redon, P., Shahzad, A., Iqbal, T., & Wijns, W. (2021). Development of a new detection algorithm to identify acute coronary syndrome using electrochemical biosensors for long-term monitoring. Bioengineering, 8(3), 28. https://doi.org/10.3390/bioengineering8020028

Röthlisberger, P., & Hollenstein, M. (2018). Aptamer chemistry. Advanced Drug Delivery Reviews, 134, 3-21. https://doi.org/10.1016/j.addr.2018.04.007

Selvam, A. P., Wangzhou, A., Jacobs, M., Wu, T., Mohan, C., & Prasad, S. (2017). Development and validation of an impedance biosensor for point-of-care detection of vascular cell adhesion molecule-1 for lupus diagnostics. Future Science OA, 3(4), FSO224. https://doi.org/10.4155/fsoa-2017-0047

Sequeira-Antunes, B., & Ferreira, H. A. (2023). Nucleic acid aptamer-based biosensors: A review. Biomedicines, 11(12), 3201. https://doi.org/10.3390/biomedicines11123201

Shaban, S. M., & Kim, D.-H. (2021). Recent advances in aptamer sensors. Sensors, 21(3), 979. https://doi.org/10.3390/s21030979

Sheraz, M., Sun, X.-F., Wang, Y., Chen, J., & Sun, L. (2024). Recent developments in aptamer-based sensors for diagnostics. Sensors, 24(23), 7432. https://doi.org/10.3390/s24237432

Stoltenburg, R., Reinemann, C., & Strehlitz, B. (2007). SELEX—A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomolecular Engineering, 24(4), 381–403. https://doi.org/10.1016/j.bioeng.2007.06.001

Tan, L. L., & Mohamad, N. S. (2025). Electrochemical aptamer-based biosensors for sepsis diagnosis: Recent advances and future perspectives (2020-2025). Biosensors, 15(7), 402. https://doi.org/10.3390/bios15070402

Tuerk, C., & Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249(4968), 505–510. https://doi.org/10.1126/science.2200121

Umapathy, V. R., Natarajan, P. M., Swamikannu, B., Moses, J., Jones, S., Chandran, M. P., & Anbumozhi, M. K. (2022). Emerging biosensors for oral cancer detection and diagnosis. Biosensors, 12(8), 498. https://doi.org/10.3390/bios12070498

Xiao, G., Li, J., Zhao, B., & Yue, Z. (2025). Photoelectrochemical aptasensors for biosensing: A review. Chemosensors, 13(9), 344. https://doi.org/10.3390/chemosensors13090344

Zambry, N. S., Ahmad Najib, M., Awang, M. S., Selvam, K., Khalid, M. F., Bustami, Y., ... & Aziah, I. (2022). Aptamer-based electrochemical biosensors for the detection of salmonella: A scoping review. Diagnostics, 12(12), 3186. https://doi.org/10.3390/diagnostics12123186


Article metrics
View details
0
Downloads
0
Citations
36
Views

View Dimensions


View Plumx


View Altmetric



0
Save
0
Citation
36
View
0
Share